Asclepix Therapeutics, Inc.

Focused on transforming the treatment of ocular diseases and cancer

Through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives.

Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self-regulating mechanisms of homeostasis that maintain our health and well-being.

June 24, 2020 in Asclepix Therapeutics, Inc., Portfolio

AsclepiX Therapeutics Announces $35 Million Series A Financing

Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE, MD, June 24,…
Read More
January 6, 2020 in Asclepix Therapeutics, Inc., Portfolio

AsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer

BALTIMORE, MD / ACCESSWIRE / January 6, 2020 / AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the…
Read More
July 16, 2019 in Asclepix Therapeutics, Inc., Portfolio

AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference

To Provide Update on AXT107 Duration of Efficacy Maintained for Over Thirteen Months to Date in Animal Models AXT107 Inhibits VEGF and Activates Tie2 with Potential Once Yearly Dosing BALTIMORE,…
Read More
April 29, 2019 in Asclepix Therapeutics, Inc., Portfolio

AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference

GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmune and the Multiple Myeloma Research Foundation (MMRF) have entered into a partnership to advance a promising new therapy…
Read More
March 25, 2019 in Asclepix Therapeutics, Inc., Portfolio

AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD

AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides for cancer, adds Steven Altschuler, MD to Board of Directors.…
Read More
March 18, 2019 in Asclepix Therapeutics, Inc., Portfolio

AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina

AXT107 exhibited a dual mechanism of action as a monotherapy, disrupting a key component of the Vascular Endothelial Growth Factor (VEGF) signaling pathway while also activating the Tie2 pathway that…
Read More
November 15, 2018 in Asclepix Therapeutics, Inc., Portfolio

AsclepiX Therapeutics Raises $5M in New Funding

BALTIMORE--(BUSINESS WIRE)--AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today announced that it has raised $5 million in Convertible Note…
Read More
November 15, 2018 in Asclepix Therapeutics, Inc., Portfolio

Baltimore-based AsclepiX Therapeutics raises $5M

Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases that are leading causes of blindness in adults. The convertible…
Read More